Q-omics provides the consensus-scored LACTBL1 profile across patient tissues and cancer cell-line models. LACTBL1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, LACTBL1 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, LACTBL1 RNA expression shows 6,207 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, LUAD, and STAD as cancer lineages where LACTBL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LACTBL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LACTBL1 survival associations across molecular data types. LACTBL1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LACTBL1 RNA expression–survival associations across cancer types. High LACTBL1 expression shows unfavorable associations in UCS, KIRC, DLBC, BRCA, LGG and UVM. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .009). Together, the overview and detailed table identify UCS as the clearest survival context for LACTBL1 RNA expression.
This table summarizes LACTBL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LACTBL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LACTBL1 shows lower tumor expression in KIRC and higher tumor expression in LUAD, HNSC, BLCA and LUSC. The LUAD box plot shows higher LACTBL1 RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .044).
This table shows molecular features associated with LACTBL1 in patient tissues and cancer cell lines. In patient samples, LACTBL1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, LACTBL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
